<DOC>
	<DOC>NCT01809379</DOC>
	<brief_summary>This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure chemotherapy in women with recurrent ovarian cancer</brief_summary>
	<brief_title>Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal carcinomatosis. The primary objective of this study is to determine the Clinical Benefit Rate (CBR) according to RECIST criteria after three cycles of PIPAC with cisplatin and doxorubicin.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>at least 2 lines of previous chemotherapy recurrent ovarian cancer patient is mobile informed consent ileus necessity of parenteral nutrition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ovarian cancer, recurrent, chemotherapy, intraperitoneal</keyword>
</DOC>